Torsdag 26 December | 23:36:20 Europe / Stockholm

Kalender

Tid*
2025-11-06 17:00 Kvartalsrapport 2025-Q3
2025-08-07 17:00 Kvartalsrapport 2025-Q2
2025-05-08 17:00 Kvartalsrapport 2025-Q1
2025-03-12 N/A Årsstämma
2025-02-12 19:30 Bokslutskommuniké 2024
2024-11-06 - Kvartalsrapport 2024-Q3
2024-08-08 - Kvartalsrapport 2024-Q2
2024-05-02 - Kvartalsrapport 2024-Q1
2024-03-14 - X-dag ordinarie utdelning GMAB 0.00 DKK
2024-03-13 - Årsstämma
2024-02-14 - Bokslutskommuniké 2023
2023-11-07 - Kvartalsrapport 2023-Q3
2023-08-03 - Kvartalsrapport 2023-Q2
2023-05-10 - Kvartalsrapport 2023-Q1
2023-03-30 - X-dag ordinarie utdelning GMAB 0.00 DKK
2023-03-29 - Årsstämma
2023-02-22 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-10 - Kvartalsrapport 2022-Q2
2022-05-11 - Kvartalsrapport 2022-Q1
2022-03-30 - X-dag ordinarie utdelning GMAB 0.00 DKK
2022-03-29 - Årsstämma
2022-02-16 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-11 - Kvartalsrapport 2021-Q2
2021-05-05 - Kvartalsrapport 2021-Q1
2021-04-14 - X-dag ordinarie utdelning GMAB 0.00 DKK
2021-04-13 - Årsstämma
2021-02-23 - Bokslutskommuniké 2020
2020-11-04 - Kvartalsrapport 2020-Q3
2020-08-12 - Kvartalsrapport 2020-Q2
2020-05-06 - Kvartalsrapport 2020-Q1
2020-03-27 - X-dag ordinarie utdelning GMAB 0.00 DKK
2020-03-26 - Årsstämma
2020-02-19 - Bokslutskommuniké 2019
2019-04-01 - X-dag ordinarie utdelning GMAB 0.00 DKK
2019-03-29 - Årsstämma
2018-11-14 - Kvartalsrapport 2018-Q3
2018-08-08 - Kvartalsrapport 2018-Q2
2018-05-08 - Kvartalsrapport 2018-Q1
2018-04-11 - X-dag ordinarie utdelning GMAB 0.00 DKK
2018-04-10 - Årsstämma
2018-02-21 - Bokslutskommuniké 2017
2017-11-08 - Kvartalsrapport 2017-Q3
2017-08-09 - Kvartalsrapport 2017-Q2
2017-05-10 - Kvartalsrapport 2017-Q1
2017-03-29 - X-dag ordinarie utdelning GMAB 0.00 DKK
2017-03-28 - Årsstämma
2017-02-22 - Bokslutskommuniké 2016
2016-11-10 - Kapitalmarknadsdag 2016
2016-11-02 - Kvartalsrapport 2016-Q3
2016-08-09 - Kvartalsrapport 2016-Q2
2016-05-10 - Kvartalsrapport 2016-Q1
2016-03-18 - X-dag ordinarie utdelning GMAB 0.00 DKK
2016-03-17 - Årsstämma
2016-02-17 - Bokslutskommuniké 2015
2015-11-03 - Kvartalsrapport 2015-Q3
2015-08-11 - Kvartalsrapport 2015-Q2
2015-05-12 - Kvartalsrapport 2015-Q1
2015-03-27 - X-dag ordinarie utdelning GMAB 0.00 DKK
2015-03-26 - Årsstämma
2015-03-02 - Bokslutskommuniké 2014
2014-11-05 - Kvartalsrapport 2014-Q3
2014-08-13 - Kvartalsrapport 2014-Q2
2014-05-07 - Kvartalsrapport 2014-Q1
2014-04-10 - X-dag ordinarie utdelning GMAB 0.00 DKK
2014-04-09 - Årsstämma
2014-03-04 - Bokslutskommuniké 2013
2013-11-06 - Kvartalsrapport 2013-Q3
2013-08-14 - Kvartalsrapport 2013-Q2
2013-05-07 - Kvartalsrapport 2013-Q1
2013-04-18 - X-dag ordinarie utdelning GMAB 0.00 DKK
2013-04-17 - Årsstämma
2013-03-07 - Bokslutskommuniké 2012
2012-11-07 - Kvartalsrapport 2012-Q3
2012-08-15 - Kvartalsrapport 2012-Q2
2012-05-09 - Kvartalsrapport 2012-Q1
2012-04-26 - X-dag ordinarie utdelning GMAB 0.00 DKK
2012-04-25 - Årsstämma
2011-11-02 - Kvartalsrapport 2011-Q3
2011-08-03 - Kvartalsrapport 2011-Q2
2011-05-11 - Kvartalsrapport 2011-Q1
2011-04-07 - X-dag ordinarie utdelning GMAB 0.00 DKK
2011-04-06 - Årsstämma
2011-02-28 - Bokslutskommuniké 2010
2010-04-22 - X-dag ordinarie utdelning GMAB 0.00 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Genmab är ett läkemedelsbolag. Bolaget är specialiserat inom forskning och utveckling av antikroppar, som huvudsakligen används vid behandling av cancerpatienter med lymfatisk leukemi och solida tumörer. Forskning och utveckling utgår ifrån bolagets egenutvecklade tekniska plattform och verksamhet innehas på global nivå. Genmab grundades 1999 och har sitt huvudkontor i Köpenhamn, Danmark.
2022-06-09 23:17:08

Company Announcement

COPENHAGEN, Denmark; June 9, 2022 Genmab A/S (Nasdaq: GMAB) announced today that it has commenced a new arbitration under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab.

This new arbitration follows from the award in the prior arbitration, where the tribunal ruled in favor of Janssen on the question as to whether Genmab is required to share in Janssen’s royalty payments to Halozyme Therapeutics, Inc. for its technology used in the subcutaneous formulation of daratumumab (marketed as DARZALEX FASPRO® in the United States), cf. Company Announcement No 14. The tribunal based its ruling on the finding that DARZALEX FASPRO constitutes a new licensed product under the license agreement.

In this new arbitration, Genmab is consequently seeking an award of $405 million plus interest in accrued milestone payments for DARZALEX FASPRO and a declaration that it is entitled to a new 13-year royalty term from the date of DARZALEX FASPRO’s first commercial sale.

Under the agreement, the arbitration will be conducted in New York pursuant to the rules of the CPR Institute for Dispute Resolution for Non-Administered Arbitration before a panel of three arbitrators. While Genmab intends to vigorously enforce its rights, the outcome of any arbitration proceeding, as well as its duration, is inherently uncertain. The arbitration will be confidential, subject to the parties’ disclosure obligations under applicable law. Other than pursuant to these obligations, Genmab does not intend to comment or provide additional information regarding the arbitration until an award on the merits or other material order is issued in the arbitration or the arbitration is otherwise concluded. While the arbitration is pending, Genmab’s various collaborations with Janssen will continue.

About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.

Contact:        
Marisol Peron, Senior Vice President, Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody® and HexElect®; DARZALEX FASPRO® is a trademark of Johnson & Johnson.


Company Announcement no. 21
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark